The waxing and waning of the speedy approval

The waxing and waning of the speedy approval

Source: 
EP Vantage
snippet: 

The FDA began restricting use of the accelerated approval pathway in earnest last year, and these efforts are now apparent in the data. Only 12% of novel drugs arrived on the market via this route last year, a substantial drop from the heady years of 2021 and 2020, an Evaluate Vantage analysis finds.